| Methods |
3‐week placebo run‐in; inclusion criteria= DBP 95‐104 mm Hg; 6‐week double‐blind treatment |
| Participants |
Perindopril 4 mg: n=27(20 males,7 females); mean age=54(9.8) years; baseline sitting SBP=161.3(12.5) mm Hg, DBP=100.4(3.8) mm Hg;
Placebo: n=26(14 males,12 females); mean age=55(8.5) years; baseline sitting SBP=159.6(17.3) mm Hg, DBP=100.7(3.2) mm Hg |
| Interventions |
Perindopril 4 mg once daily;
Placebo |
| Outcomes |
SBP/DBP using mercury sphygmomanometer;
WDAE |
| Notes |
BP change and SD of change not reported, endpoint BP and SD reported; imputed endpoint SD for SD of change; BP data from Table 3, p. 190; time and position of BP measurement not reported; Jadad score=3; funding source= not reported |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
